Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
November 10 2017 - 8:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced data
from preclinical studies with ADU-1604, the company’s humanized
anti-CTLA-4 monoclonal antibody. Data from these in vitro and
in vivo studies demonstrate the potency of ADU-1604 and its ability
to inhibit tumor growth and enhance T cell-dependent antibody
responses. These data, which will be highlighted later today
in a poster presentation (Poster #335) at the 32nd Annual Meeting
of the Society for Immunotherapy of Cancer (SITC), underscore the
potential application of ADU-1604 for the treatment of multiple
cancer types, either as monotherapy or in combination with other
therapies.
“These data from preclinical studies of
ADU-1604, a novel anti-CTLA-4 product candidate derived from our
proprietary B-select antibody platform, are encouraging and provide
support to file an Investigational New Drug Application to advance
ADU-1604 into clinical studies,” stated Andrea van Elsas, Ph.D.,
chief scientific officer of Aduro Biotech. “As a company with
multiple programs and proprietary technology platforms, we are well
positioned to leverage our product candidates, as monotherapies and
in rational combinations, to develop new treatment options for
patients in need.”
Presentation Title: Characterization of a novel
differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in
vivo Researchers conducted in vitro and in vivo studies
comparing ADU-1604 to benchmark anti-CTLA-4 antibodies 10D1
(‘ipilimumab’) and CP-675,206 (‘tremelimumab’). Data from these
studies demonstrate that ADU-1604 binds to a unique epitope on a
human CTLA-4 (hCTLA-4) and is at least comparable to benchmarks in
functionality. Data from in vivo studies using a well-established
humanized mouse model of non-small cell lung cancer and a non-human
primate model, demonstrate that ADU-1604 inhibits tumor growth and
enhances T cell responses, respectively. Further, proof of concept
studies in syngeneic mouse models demonstrate that anti-CTLA-4
further enhances anti-tumor activity when used in combination with
ADU-S100 (also known as MIW815), Aduro’s lead investigational STING
agonist, and in combination with Aduro’s proprietary immunotherapy
platform of live-attenuated double-deleted Listeria monocytogenes
strains (LADD).
About CTLA-4Cytotoxic
T‐lymphocyte‐associated protein 4 (CTLA‐4) is a negative regulator
of T‐cell responses and is an immune checkpoint. Blocking CTLA-4
using antibodies may produce an anti-tumor response by enhancing T
cell activation and their cancer cell killing activity in the
tumor. This therapeutic target has been clinically validated by
others in advanced melanoma. Aduro is developing a proprietary
humanized anti-CTLA-4 antibody (ADU-1604) that binds to a unique
epitope and its potency has been demonstrated in vitro and in vivo.
Based on preclinical studies, Aduro believes that ADU-1604 when
combined with innate and adaptive immune cell stimulators, such as
STING agonists and cancer vaccines, can display an amplified
anti-tumor effect against poorly immunogenic tumors. Aduro’s CTLA-4
antibody is being advanced through IND-enabling
studies.
About AduroAduro Biotech, Inc.
is an immunotherapy company focused on the discovery, development
and commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, gastric, ovarian, lung and prostate cancers.
Additionally, a personalized form of LADD, or pLADD, is in Phase 1
development utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the STING receptor in immune
cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and preclinical development, including
BION-1301, an anti-APRIL antibody. Aduro is collaborating with
leading global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding our intentions or current
expectations concerning, among other things, the potential for
ADU-1604 alone or in combination with other therapies, our ability
to leverage our product candidates, our technology platforms,
plans, and the potential for eventual regulatory approval of our
product candidates. In some cases, you can identify these
statements by forward-looking words such as “may,” “will,”
“continue,” “anticipate,” “intend,” “could,” “project,” “seek”,
“expect” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, our history of
net operating losses and uncertainty regarding our ability to
achieve profitability, our ability to develop and commercialize our
product candidates, our ability to use and expand our technology
platforms to build a pipeline of product candidates, our ability to
obtain and maintain regulatory approval of our product candidates,
our ability to operate in a competitive industry and compete
successfully against competitors that have greater resources than
we do, our reliance on third parties, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail under
the heading “Risk Factors” contained in our quarterly report on
Form 10-Q for the quarter ended September 30, 2017, which is on
file with the Securities and Exchange Commission. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs510 809 9264
Media Contact:Susan Lehner 510 809 2137press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024